Aflibercept Injection for Proliferative Diabetic Retinopathy

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 18 years * Diagnosed with proliferative diabetic retinopathy (PDR) requiring pars plana vitrectomy (PPV) * Best corrected visual acuity in the study eye between 20/40 to light perception (LP) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart Exclusion Criteria: * Pregnancy (positive urine pregnancy test) or lactation * Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device (IUD), or contraceptive hormone implant or patch. * Participation in a study of an investigational drug or device within the past 30 days prior to enrolling in the study * For previously treated subjects - * Prior treatment with anti-vascular endothelial growth factor (anti-VEGF) therapy in the study eye within 28 days of Screening * Prior treatment with triamcinolone in the study eye within 6 months of Screening. * Prior treatment with dexamethasone in the study eye within 30 days of Screening * Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Baseline * History of vitrectomy surgery, submacular surgery, or other surgical intervention for PDR in the study eye * Active intraocu…